Zevenbergen Capital Investments LLC Acquires 101,782 Shares of DexCom, Inc. $DXCM

Key Points

• Zevenbergen Capital Investments LLC increased its stake in DexCom, Inc. by 19.5%, acquiring an additional 101,782 shares in the second quarter, bringing its total ownership to 623,335 shares.
• Multiple institutional investors have significantly increased their stakes in DexCom, with Golden State Wealth Management LLC raising its holding by 211.2%.
• Analysts maintain a favorable outlook on DexCom, with several firms raising their price targets, including Mizuho and UBS Group, setting targets at $100.00 and $106.00, respectively.

Zevenbergen Capital Investments LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 19.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 623,335 shares of the medical device company's stock after purchasing an additional 101,782 shares during the quarter. DexCom comprises 1.1% of Zevenbergen Capital Investments LLC's investment portfolio, making the stock its 28th biggest position. Zevenbergen Capital Investments LLC owned 0.16% of DexCom worth $54,411,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Golden State Wealth Management LLC raised its stake in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares in the last quarter. Private Trust Co. NA raised its stake in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after purchasing an additional 335 shares in the last quarter. Farther Finance Advisors LLC raised its stake in DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after purchasing an additional 702 shares in the last quarter. Dynamic Advisor Solutions LLC raised its stake in DexCom by 34.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after purchasing an additional 1,333 shares in the last quarter. Finally, Stonebridge Financial Group LLC raised its stake in DexCom by 944.5% in the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock valued at $220,000 after purchasing an additional 2,909 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on DXCM. Argus began coverage on DexCom in a research note on Thursday, August 21st. They issued a "buy" rating and a $100.00 price target for the company. Mizuho upped their price objective on DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. UBS Group upped their target price on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Citigroup restated a "buy" rating and set a $102.00 price target (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Morgan Stanley increased their price target on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Activity

In other news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,237 shares of company stock valued at $1,263,480. 0.32% of the stock is owned by insiders.

DexCom Stock Up 0.3%

DXCM stock opened at $76.22 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $29.89 billion, a PE ratio of 52.93, a PEG ratio of 1.59 and a beta of 1.48. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The stock has a 50-day simple moving average of $80.88 and a two-hundred day simple moving average of $78.64.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company's revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter last year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.